As stated earlier, Toker et al. (34) also reported that EOC Tregs exhibit a distinct phenotype that have higher levels of ICOS compared to melanoma Tregs, which may explain why melanoma patients have responded well to ICOS agonist interventions as these might primarily act on cytotoxic T cells in melanoma rather than Tregs. This evidence concerns the gene ICOS and melanoma.